NR3C2 and type 2 diabetes mellitus: Recently published results show that new MR antagonists reduce the risk of chronic kidney disease progression and cardiovascular events in patients with chronic kidney disease and type 2 diabetes regardless of pre-existing cardiovascular problems (Bakris et al., 2020; Filippatos et al., 2021).